Epacadostat
Epacadostat is a small molecule pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against indoleamine 2,3-dioxygenase 1.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
60 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Carcinoma | D002277 | — | C80.0 | 1 | 3 | 3 | — | — | 6 |
| Head and neck neoplasms | D006258 | — | — | 1 | 1 | 1 | — | — | 2 |
| Renal cell carcinoma | D002292 | EFO_0000376 | — | 1 | 1 | 1 | — | — | 2 |
| Transitional cell carcinoma | D002295 | — | — | — | — | 2 | — | — | 2 |
| Melanoma | D008545 | — | — | 1 | 1 | 1 | — | — | 2 |
| Squamous cell carcinoma of head and neck | D000077195 | — | — | — | — | 1 | — | — | 1 |
| Squamous cell carcinoma | D002294 | — | — | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Non-small-cell lung carcinoma | D002289 | — | — | 1 | 2 | — | — | — | 3 |
| Lung neoplasms | D008175 | — | C34.90 | 1 | 3 | — | — | — | 3 |
| Neoplasms | D009369 | — | C80 | 2 | 1 | — | — | — | 2 |
| Stomach neoplasms | D013274 | EFO_0003897 | C16 | 1 | 2 | — | — | — | 2 |
| Colorectal neoplasms | D015179 | — | — | 1 | 1 | — | — | — | 1 |
| Sarcoma | D012509 | — | — | — | 1 | — | — | — | 1 |
| Recurrence | D012008 | — | — | — | 1 | — | — | — | 1 |
| Esophageal neoplasms | D004938 | — | C15 | — | 1 | — | — | — | 1 |
| Adenocarcinoma | D000230 | — | — | — | 1 | — | — | — | 1 |
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | — | 1 | — | — | — | 1 |
Show 9 more
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Epacadostat |
| INN | epacadostat |
| Description | Epacadostat (previously INCB24360) is an investigational drug for cancer. Epacadostat is an inhibitor of indoleamine 2,3-dioxygenase-1 (IDO1). Epacadostat inhibits IDO1 by competitively blocking it, without interfering with IDO2 or tryptophan 2,3-dioxygenase (TDO). It has antitumor activity in some models, though is most effective when combined with other immunotherapy agents.
|
| Classification | Small molecule |
| Drug class | enzyme inhibitors: indoleamine 2, 3-dioxygenase 1 (IDO1) inhibitors |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | NS(=O)(=O)NCCNc1nonc1/C(=N/O)Nc1ccc(F)c(Br)c1 |
Identifiers
| PDB | — |
| CAS-ID | 1204669-37-3 |
| RxCUI | — |
| ChEMBL ID | CHEMBL3545369 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB11717 |
| UNII ID | 71596A9R13 (ChemIDplus, GSRS) |
Target
Agency Approved
IDO1
IDO1
Alternate
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,957 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
98 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use